Introduction
A cytosine/thymine substitution at a putative binding site for the steroidogenic transcription factor (1), 344C/T polyhypertension and cardiovascular disease are still uncertain. Recently, we investigated the effects of this polymorphism on blood pressure (BP) by means of ambulatory BP monitoring (ABPM) in a cohort of Japanese population with the 344C/T polymorphism (10) . The results demonstrated the possibility that this genetic polymorphism influences circadian BP variation and the prevalence of cardiovascular disease in the Japanese population. Another Japanese study, however, reported a lack of association between this polymorphism and either hypertension or cardiovascular disease (11) , indicating that further investigations will be needed.
White and Slutsker reported the presence of three genetic polymorphisms in CYP11B2, 344C/T at the promoter region, a conversion in intron 2 from the CYP11B2 sequence to the CYP11B1 sequence, and R173K in exon 3 (12) . We previously reported an absolute linkage disequilibrium between the 344C/T and R173K polymorphisms, and a close linkage between 344T and the intron 2 sequence conversion in the general Japanese population, forming the three allelic haplotypes (13) . In this study we failed to find the V386A mutation of CYP11B2 (13) , which has been reported in Caucasians (4) . These genetic polymorphisms in CYP11B2 should still be individually investigated, since one effective genetic variant may influence the analyses of another genetic factor.
In addition to the CYP11B2 344C/T polymorphism, we have completed investigations on major genetic polymorphisms in the renin-angiotensin system, angiotensinogen (AGT) M235T, angiotensin converting enzyme (ACE) I/D, and angiotensin II type 1 receptor (AT1) A/C 1166 , in the same Japanese population, who underwent ABPM (14-16). Although we have not reached a final determination of the genetic factors involved in hypertension, our results indicated that the polymorphisms could be classified into two groups, those possibly associated with clinical manifestations related to hypertension (10, 15) , and those showing little association (14, 16) . In further studies with a larger population who measured their BP at home (home BP), subpopulation analyses revealed a difference in pulse pressure among the genotypes of AGT M235T, which is included in the former group (17) . On the other hand, another home BP study confirmed the lack of association between hypertension and the ACE I/D polymorphism (14) . Therefore, the present study was designed to re-examine the association between the CYP11B2 344C/T polymorphism and home BP, as well as to investigate another genetic polymorphism in CYP11B2 that has close linkage disequilibrium with the CYP11B2 344C/T polymorphism.
Methods

Subjects
The study involved subjects who participated in our home BP measurement and/or ABPM and genetic analysis projects in the rural community of Ohasama, Iwate Prefecture, Japan. The characteristics of this area and the details of the study projects have been reported previously (10, 18, 19) . Our initial cohort consisted of 1,245 subjects who participated in home BP measurement and 802 subjects who participated in ABPM (761 subjects were included in both projects), and all subjects provided written informed consent (10, 14) . However, three subjects withdrew from the study, and thus the final study group consisted of 1,242 subjects with home BP and 801 subjects with ABPM. The number of subjects participating in both BP measurements was 760 (17) . The clinical characteristics of the home BP subjects are shown in Table  1 . The study protocol was approved by the Institutional Review Board of Tohoku University School of Medicine and by the Department of Health of the Ohasama Town Government.
Hypertensive subjects were defined as subjects receiving antihypertensive drugs and/or whose home BP was higher than 135 mmHg in systole and/or higher than 85 in diastole.
Genotyping
Three genetic polymorphisms of CYP11B2, 344C/T at the promoter region, a conversion in intron 2 from the CYP11B2 sequence to that of CYP11B1, and R173K in exon 3, were examined as reported previously (13) . Briefly, 344C/T and R173K polymorphisms were genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP), and the presence or absence of intron 2 conversion was determined by allele-specific PCR (13) .
Home BP Measurements and ABPM
All subjects were asked to measure BP at home once in the morning within 1 h of waking, after micturition but before drug ingestion, if needed, and before breakfast, in a sitting position after 3 min of rest. Fully automatic, digital display devices (HEM 401C, 701C, 703C or 747IC; Omron Life Science, Kyoto, Japan) were used for the home BP measurements. Public health nurses or hospital nurses calibrated the devices and instructed the subjects on how to measure BP. The home BP of an individual was defined as the mean of all measurements obtained for that individual. The mean number of home BP measurements was 24.6 6.6 (mean SD); the range was 3-105. Hypertension was defined as being treated with antihypertensive medication and/or having home BP values of more than 135 mmHg in systole and/or 85 mmHg in diastole (20) .
The details of ABPM have been described previously (10, 15) . In brief, ambulatory BP was monitored every 30 min using a fully automatic device (ABPM630; Nippon Colin, Komaki, Japan) which met the criteria of the Association for the Advancement of Medical Instrumentation. Nocturnal systolic and diastolic BP fall were calculated as: (daytime BP nighttime BP) 100/daytime BP (%).
Data Analysis
Information on smoking status and use of antihypertensive medication was obtained from questionnaires sent to the subjects at the time of home BP measurements. We also used the medical records at Ohasama Hospital. SAS software, Version 6.12 (SAS Institute Inc., Cary, USA) was used for all statistical analyses. Student's two-tailed t-test, one-way analysis of variance (ANOVA), analysis of covariance (ANCOVA), χ 2 test and logistic regression analyses were used as appropriate. Data are shown as the means SD. Values of p 0.05 were considered to represent statistically significant differences.
Results
Clinical Parameters Based on CYP11B2
344C/T Genotypes and Sequence Conversion in Intron 2
Our previous study had already reported the distribution of 344C/T and intron 2 genotypes in CYP11B2 (13) , and the genotypic frequencies of these polymorphisms in the present study were quite similar to those of our previous study (13) . The genotype frequency of CYP11B2 344C/T was not deviated from principle equilibrium ( χ Clinical characteristics based on genetic polymorphisms are demonstrated in Table 2 . Since the number of subjects homologous for intron 2 conversion was limited (n 29) and the genotype frequency of this genetic polymorphism was deviated from principle equilibrium ( χ 2 12.189, p 0.001), the genotypes of CYP11B2 intron 2 are classified into two groups according to the presence or absence of intron 2 conversion. Although the BP levels were unaltered, genotypes of CYP11B2 344C/T were associated with a difference in the prevalence of hypertension ( p 0.016) and antihypertensive medication ( p 0.040). After the adjustment by age, gender, body mass index (BMI), and smoking status, statistical significance was conserved for both the prevalence of hypertension and antihypertensive medication. The multiple logistic regression analysis indicated that the odds ratio for hypertension with the number of T alleles was 1.25 (95% confidence interval (CI) 1.05-1.50, p 0.015). That for antihypertensive medication was 1.25 (95% CI 1.04-1.50, p 0.029).
The prevalence of cardiovascular diseases tended to be different among the three genotypes of CYP11B2 344C/T ( p 0.10). Since our previous study on the basis of ABPM demonstrated a significantly greater prevalence in subjects possessing the 344T allele (10), this parameter was further examined between subjects with this allele (n 1,074) and those without (n 168). The results again demonstrated the On the other hand, there were no significant differences in ABPM data between subjects with and those without the CYP11B2 intron conversion. Table 3 shows the additional analyses of these polymorphisms in ABPM subjects, again indicating the lack of difference in BP levels, or in the nocturnal BP decline.
Subpopulation Analyses
Subpopulation analyses based on age (40 ≤ age 60 or 60 ≤ age) or on gender were performed on all three polymorphisms mentioned above as part of our previous genetic studies by home BP project (14, 17) . We did not find a specific subpopulation in which the frequency of hypertension was significantly associated with CYP11B2 344C/T polymorphism. In the older population (60 ≤ age, n 678), how- 
Discussion
In the present study, genetic variants of CYP11B2 were analyzed together in the general Japanese population. The CYP11B2 344C/T polymorphism, which is located at the promoter region, was significantly associated with a higher proportion of hypertensive or antihypertensive medication. The T variant of this polymorphism was associated with higher prevalence of cardiovascular diseases, especially in the older population (60 ≤ age). The presence of sequence conversion in CYP11B2 intron 2, by contrast, was not associated with any clinical parameters related to hypertension, though this genetic polymorphism possesses strong linkage disequilibrium with 344C/T in CYP11B2. Investigations on the basis of ABPM demonstrated that this sequence conversion in intron 2 had no influence on the circadian BP variation. Since our previous study by ABPM has already demonstrated the effects of CYP11B2 344C/T polymorphism on circadian BP variation and on the prevalence of cardiovascular diseases (10), the present study confirmed that this genetic polymorphism is the genetic factor related to clinical manifestations, including hypertension, in the Japanese population.
The subpopulation analysis demonstrated that the 344T allele was strongly associated with the prevalence of cardiovascular diseases in the older population, whereas there was no association in the younger population (40 ≤ age 60). On the other hand, the effect of this allele on the prevalence of hypertension was significant in the whole population (40 ≤ age), but not in any specific subpopulations. Essential hypertension occurs from middle age, and cardiovascular diseases, whether occurring as a complication of hypertension or occurring independently-tend to occur later. Consequently, genetic effects on the incidence of hypertension, if any, may appear earlier than those on the prevalence of cardiovascular diseases. In this sense, the present findings by subpopulation analysis further confirmed the presence of the clinical effects of the CYP11B2 344T allele. Although the genetic factors had no direct influence on BP level even in this population, the basal clinical characteristics of the present subjects (Table 1 ) demonstrated a slight elevation of BP in hypertensive subjects. This indicates that most of the hypertensive patients were well treated in this community, and thus the genetic effects on BP level may have been modified by the antihypertensive medication.
We have completed our lines of investigations on major genetic polymorphisms in the renin-angiotensin-aldosterone system, including CYP11B2 344C/T polymorphism, based on BP values of ABPM (10, (14) (15) (16) . Although the ACE I/D and AT1 A/C 1166 polymorphisms were not associated with any clinical parameters related to hypertension (14-16), circadian BP was altered in subjects homologous for AGT 235M (15) . Further investigation using subjects with home BP additionally demonstrated a wider pulse pressure in the older subpopulation with this genotype (17) , whereas such additional analyses confirmed the lack of association between the ACE I/D polymorphism and hypertension (14) . Thus, additional investigations based on home BP may better elucidate the characteristics of individual genetic factors. The present study also demonstrated that the CYP11B2 344C/T polymorphism was significantly associated with hypertension in subjects aged 40 and over and with cardiovascular diseases in subjects aged 60 and over. In contrast, both the analysis by ABPM and that by home BP showed a lack of association between gene conversion in CYP11B2 intron 2 and any clinical manifestations. These findings suggest that CYP11B2 344C/T polymorphism is one of the independent genetic factors, albeit a weak one, related to hypertension in the Japanese population.
The physiological role of the CYP11B2
344T allele should be carefully discussed, since this is the major variant in the general Japanese population (5). Previously we have proposed the explanation that high salt sensitivity or excess mineral corticoid secretion may influence statistical analyses based on a general population, since salt sensitivity or amount of salt intake, aldosterone secretion, and circadian BP rhythm are closely linked (21) (22) (23) (24) . In addition, Davies et al. have suggested that 344C/T polymorphism affects aldosterone secretion (5). Therefore, it is possible that the 344T allele is physiologically advantageous for absorbing or maintaining sodium, and high salt intake, in turn, could induce extra body sodium and fluid accumulation, leading to disturbance of BP control or circadian BP variation in subjects having the 344T allele. Detailed hormonal and physiological examinations under condition of strictly regulated salt intake will be required to determine the physiological effects of this genetic factor.
In conclusion, the present results indicate that the T allele of the CYP11B2 344C/T polymorphism can be considered an independent risk factor for hypertension or atherosclerotic diseases in the general Japanese population. The molecular mechanisms or environmental factors that mediate the adverse effects of the 344T genotype remain to be elucidated. 
